Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS
$125m Upfront For InnoCare
Executive Summary
BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.
You may also be interested in...
Five Multiple Sclerosis R&D Updates From ECTRIMS
With the virtual doors about to close on the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, Scrip takes a look at some of the highlights, including data for Merck KGaA and Sanofi’s new BTK inhibitors and research showing the impact of MS therapies on COVID-19 vaccine response.
Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
Hotter Than Oncology? China Immunology Players Raise $650m
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.